Pricing Log in Create free account
Saturday 17 October 2026 Export TECH’s income statement to Excel — free account

Bio-Techne Corp

TECH Healthcare Biotechnology

Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025. In the quarter to June 2026, revenue grew 1.33%, EPS grew 418.2%, free cash flow fell 6.83% and total debt fell 42.2%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for three consecutive years.

72.54 0.02 +0.03%
Market cap
$11.4B
P/E
62.0×
Fwd P/E
37.6×
Dividend yield
0.44%
F-score
9/9
Altman Z
15.50
Beneish M
−2.52
Dividend safety
78/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Bio-Techne Corp (TECH) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Bio-Techne Corp (TECH) trades at a EV/EBITDA of 32.2×. Over the past ten years it has ranged from 16.7× (January 2016) to 64.6× (September 2021); the current reading is higher than 49% of that period. That is above the Biotechnology industry median of 0.6× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2026 31.4× (19.74%)
FY2025 39.1× 8.59%
FY2024 36.0× 12.68%
FY2023 32.0× (6.52%)
FY2022 34.2× (36.66%)
FY2021 54.0× 27.50%
FY2020 42.4× 15.54%
FY2019 36.7× 28.78%
FY2018 28.5× 12.50%
FY2017 25.3× 16.80%

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 31.4× (2.37%)
Mar 2026 32.2× (23.38%)
Dec 2025 42.0× 2.87%
Sep 2025 40.8× 4.30%
42 more quarters

Against its own ten years

Low 16.7× High 64.6×
Ten-year median 32.4×
Current reading's percentile 49

EV/EBITDA against peers

Company EV/EBITDA
PCVX Vaxcyte, Inc. compare n/m
BBIO BridgeBio Pharma, Inc. compare n/m
IBRX ImmunityBio, Inc. compare n/m
MDGL Madrigal Pharmaceuticals, Inc. compare n/m
SMMT Summit Therapeutics PLC compare n/m
TECH Bio-Techne Corp 32.2×
KRYS Krystal Biotech, Inc. compare 41.6×
BMRN BioMarin Pharmaceutical Inc. compare 46.7×
CORT Corcept Therapeutics Incorporated compare 3,040×
Biotechnology industry median 0.6×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on TECH